0K4 Stock Overview Together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Akero Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Akero Therapeutics Historical stock prices Current Share Price US$27.02 52 Week High US$32.78 52 Week Low US$16.50 Beta -0.24 1 Month Change -10.53% 3 Month Change 3.76% 1 Year Change 23.95% 3 Year Change 44.49% 5 Year Change 50.95% Change since IPO 60.49%
Recent News & Updates
Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024 Nov 16
Akero Therapeutics, Inc. Provides Business Update Nov 08
New major risk - Revenue and earnings growth Aug 12
Insufficient new directors May 01
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer Apr 30 Akero Therapeutics, Inc., Annual General Meeting, Jun 07, 2024 See more updates
Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024 Nov 16
Akero Therapeutics, Inc. Provides Business Update Nov 08
New major risk - Revenue and earnings growth Aug 12
Insufficient new directors May 01
Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer Apr 30 Akero Therapeutics, Inc., Annual General Meeting, Jun 07, 2024
Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology Mar 08 Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million. Mar 07
Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million. Mar 06
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
New major risk - Revenue and earnings growth Mar 02
Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program Dec 18
Co-Founder recently sold €404k worth of stock Nov 24
Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins Oct 11
New minor risk - Share price stability Oct 11
Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH Oct 10
Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology Oct 05
Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023 Aug 29 Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index
Co-Founder & Chief Scientific Officer recently sold €1.9m worth of stock Jun 25
Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study Jun 06
Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy Jan 11
Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study Dec 22
Independent Director recently sold €1.1m worth of stock Dec 03
Independent Director recently sold €12m worth of stock Oct 29 Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million. Sep 16
Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million. Sep 15
Akero Therapeutics, Inc. Releases Topline Data from HARMONY Sep 14
Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis Aug 25
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis Jun 28 Akero Therapeutics, Inc. announced that it expects to receive $100 million in funding from Hercules Capital, Inc. Jun 17
High number of new directors May 31
High number of new directors Apr 27
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients Feb 09
Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions, Demonstrating that Improvements in Adipose Tissue Metabolism Contributed Substantially to Improved Liver Health and Better Glycemic Control in Efruxifermin (EFX)-treated Pre-Cirrhotic NASH Patients Jun 26
New 90-day high: €27.80 Mar 10
Akero Therapeutics, Inc. Initiates Phase 2B Harmony Study of Efruxifermin (Efx) for the Treatment of NASH Feb 25
New 90-day high: €27.00 Feb 10
New 90-day high: €25.00 Jan 21
New 90-day low: €20.20 Jan 06
New 90-day low: €20.60 Dec 22
Akero Therapeutics, Inc. Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy Nov 14
New 90-day low: €23.80 Oct 16
Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients in Ongoing Balanced Study Oct 04
Akero Therapeutics to Present Data from Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk at The Liver Meeting® 2020 Oct 03
New 90-day low: €26.20 Oct 01
Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance Sep 26
Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $188.213976 million. Jul 08
Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Microcap Value Index Jul 02 Shareholder Returns 0K4 DE Biotechs DE Market 7D -1.5% 1.2% -0.3% 1Y 23.9% -14.3% 7.0%
See full shareholder returns
Return vs Market: 0K4 exceeded the German Market which returned 7% over the past year.
Price Volatility Is 0K4's price volatile compared to industry and market? 0K4 volatility 0K4 Average Weekly Movement 7.3% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0K4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0K4's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 2017 60 Andrew Cheng akerotx.com
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases.
Show more Akero Therapeutics, Inc. Fundamentals Summary How do Akero Therapeutics's earnings and revenue compare to its market cap? 0K4 fundamental statistics Market cap €1.92b Earnings (TTM ) -€228.07m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0K4 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$237.22m Earnings -US$237.22m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 17:28 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Akero Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Zemansky BofA Global Research Alexandria Hammond BofA Global Research Edward Nash Canaccord Genuity
Show 13 more analysts 
